# An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

> **NCT03765229** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03765229
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-22
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765229, "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03765229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*